Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
Vol. 3, No. 1/2, Special Issue: International Applications of Productivity and Efficiency Analysis (June 1992), pp. 153-169 (17 pages) Frontier production functions are important for the prediction of ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback